5. CONCLUSION
In conclusion, our findings demonstrated that IL-10 is a potential target for the treatment of SFTSV and SARS-CoV-2-related immunopathology.
Therefore, blockade of IL-10 signalling using monoclonal antibodies against the IL-10 receptor is a promising therapeutic for treating fatal SFTS and severe and critically ill COVID-19 patients.[7, 10]